董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Howard L. Weiner | 男 | Director | 75 | 0.85万美元 | 未持股 | 2021-03-08 |
| Robin E. Abrams | 女 | Executive Chairperson | 56 | 59.91万美元 | 未持股 | 2021-03-08 |
| Richard S. Nelson | 男 | Director | 49 | 未披露 | 6.19 | 2021-03-08 |
| John A. Fry | 男 | Director | 59 | 1.05万美元 | 未持股 | 2021-03-08 |
| Noel J. Spiegel | 男 | Director | 72 | 8.39万美元 | 未持股 | 2021-03-08 |
| Hersh Kozlov | 男 | Director | 72 | 0.76万美元 | 未持股 | 2021-03-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen L. Holcombe | 男 | President and Chief Executive Officer | 63 | 140.10万美元 | 未持股 | 2021-03-08 |
| Robin E. Abrams | 女 | Executive Chairperson | 56 | 59.91万美元 | 未持股 | 2021-03-08 |
| Rudy C. Howard | 男 | Executive Vice President and Chief Financial Officer | 64 | 93.49万美元 | 未持股 | 2021-03-08 |
| Rudy C. Howard | 男 | Executive Vice President and Chief Financial Officer | 62 | 未披露 | 未持股 | 2021-03-08 |
董事简历
中英对照 | 中文 | 英文- Howard L. Weiner
-
HowardL.Weiner于2017年7月被任命为我们的董事会成员。韦纳博士，Robert L.Kroc自1997年以来是哈佛医学院神经学教授，自1985年以来是Brigham&Women&8217；s医院神经疾病中心的联合主任，他开创了使用免疫疗法治疗多发性硬化症的先河，并调查了这种疾病的免疫异常。他还开创了粘膜免疫系统用于治疗自身免疫性疾病和其他疾病的先河，包括阿尔茨海默氏症和Lou Gehrig病。根据他的研究成果，疫苗正在多发性硬化症、糖尿病以及最近的阿尔茨海默氏症中进行测试。Weiner博士就读于达特茅斯学院（Dartmouth College），并在科罗拉多大学医学院（University of Colorado School of Medicine）获得医学博士学位。
Howard L. Weiner was appointed to our Board of Directors in July 2017. Dr. Weiner, the Robert L. Kroc Professor of Neurology at the Harvard Medical School since 1997 and Co-Director of the Center for Neurologic Diseases at the Brigham & Women’s Hospital since 1985 pioneered the use of immunotherapy for the treatment of multiple sclerosis and has investigated immune abnormalities in the disease. He also pioneered the use of the mucosal immune system for the treatment of autoimmune and other diseases, including Alzheimer’s disease and Lou Gehrig’s disease. Based on his work, vaccines are being tested in multiple sclerosis, diabetes, and most recently in Alzheimer’s disease. Dr. Weiner attended Dartmouth College, and received his M.D. from the University of Colorado School of Medicine. - HowardL.Weiner于2017年7月被任命为我们的董事会成员。韦纳博士，Robert L.Kroc自1997年以来是哈佛医学院神经学教授，自1985年以来是Brigham&Women&8217；s医院神经疾病中心的联合主任，他开创了使用免疫疗法治疗多发性硬化症的先河，并调查了这种疾病的免疫异常。他还开创了粘膜免疫系统用于治疗自身免疫性疾病和其他疾病的先河，包括阿尔茨海默氏症和Lou Gehrig病。根据他的研究成果，疫苗正在多发性硬化症、糖尿病以及最近的阿尔茨海默氏症中进行测试。Weiner博士就读于达特茅斯学院（Dartmouth College），并在科罗拉多大学医学院（University of Colorado School of Medicine）获得医学博士学位。
- Howard L. Weiner was appointed to our Board of Directors in July 2017. Dr. Weiner, the Robert L. Kroc Professor of Neurology at the Harvard Medical School since 1997 and Co-Director of the Center for Neurologic Diseases at the Brigham & Women’s Hospital since 1985 pioneered the use of immunotherapy for the treatment of multiple sclerosis and has investigated immune abnormalities in the disease. He also pioneered the use of the mucosal immune system for the treatment of autoimmune and other diseases, including Alzheimer’s disease and Lou Gehrig’s disease. Based on his work, vaccines are being tested in multiple sclerosis, diabetes, and most recently in Alzheimer’s disease. Dr. Weiner attended Dartmouth College, and received his M.D. from the University of Colorado School of Medicine.
- Robin E. Abrams
-
Robin E.Abrams于2020年12月被任命为我们的董事会主席。在此之前，Abrams女士and General Counsel担任执行Vice President。Abrams女士目前还担任SIGA Technologies的总法律顾问兼首席行政官。在加入VTV之前，艾布拉姆斯女士在普渡制药公司（Purdue Pharma L.P.）任职14年，在那里她担任Vice President和副总法律顾问。在Purdue时，Abrams女士是Purdue与政府实体的主要法律联系，包括司法部，缉毒署和其他联邦，州和地方当局。Abrams女士还担任普渡公司与国会委员会和核心小组的联络人，这些委员会和核心小组专注于与普渡公司产品相关的问题，例如阿片类药物产品的滥用和转移。Abrams女士还监管Purdue&8217；的法律监管，就业和政府诉讼集团。在普渡之前，Abrams女士曾担任纽约南区美国助理检察官，在此之前，Abrams女士曾担任纽约东区联邦地区法院当时的首席法官Jack B.Weinstein的书记员。Abrams女士在纽约大学法学院（New York University School of Law）获得法学博士学位，在康奈尔大学（Cornell University）获得文学学士学位。Abrams女士在制药和生物技术行业拥有丰富的专业知识，担任了近20年的高级法律职务。
Robin E. Abrams was appointed Chairperson of our Board of Directors in December 2020. Prior to that, Ms. Abrams served as Executive Vice President and General Counsel. Ms. Abrams also currently serves as General Counsel and Chief Administrative Officer for SIGA Technologies. Prior to joining vTv, Ms. Abrams had a fourteen-year tenure at Purdue Pharma L.P., where she served as Vice President and Associate General Counsel. While at Purdue, Ms. Abrams was Purdue’s primary legal contact with government entities including the Department of Justice, Drug Enforcement Administration and other federal, state and local authorities. Ms. Abrams also served as Purdue’s liaison with congressional committees and caucuses that focused on issues related to Purdue’s products, such as abuse and diversion of opioid pharmaceutical products. Ms. Abrams also oversaw Purdue’s legal regulatory, employment, and government litigation groups. Prior to Purdue, Ms. Abrams served as an Assistant United States Attorney in the Southern District of New York and prior to that, Ms. Abrams clerked for then-Chief Judge Jack B. Weinstein, federal District Court, Eastern District of New York. Ms. Abrams earned her Juris Doctor degree from New York University School of Law, and her Bachelor of Arts degree from Cornell University. Ms. Abrams has extensive expertise in the pharmaceutical and biotechnology industries with nearly 20 years in senior legal roles. - Robin E.Abrams于2020年12月被任命为我们的董事会主席。在此之前，Abrams女士and General Counsel担任执行Vice President。Abrams女士目前还担任SIGA Technologies的总法律顾问兼首席行政官。在加入VTV之前，艾布拉姆斯女士在普渡制药公司（Purdue Pharma L.P.）任职14年，在那里她担任Vice President和副总法律顾问。在Purdue时，Abrams女士是Purdue与政府实体的主要法律联系，包括司法部，缉毒署和其他联邦，州和地方当局。Abrams女士还担任普渡公司与国会委员会和核心小组的联络人，这些委员会和核心小组专注于与普渡公司产品相关的问题，例如阿片类药物产品的滥用和转移。Abrams女士还监管Purdue&8217；的法律监管，就业和政府诉讼集团。在普渡之前，Abrams女士曾担任纽约南区美国助理检察官，在此之前，Abrams女士曾担任纽约东区联邦地区法院当时的首席法官Jack B.Weinstein的书记员。Abrams女士在纽约大学法学院（New York University School of Law）获得法学博士学位，在康奈尔大学（Cornell University）获得文学学士学位。Abrams女士在制药和生物技术行业拥有丰富的专业知识，担任了近20年的高级法律职务。
- Robin E. Abrams was appointed Chairperson of our Board of Directors in December 2020. Prior to that, Ms. Abrams served as Executive Vice President and General Counsel. Ms. Abrams also currently serves as General Counsel and Chief Administrative Officer for SIGA Technologies. Prior to joining vTv, Ms. Abrams had a fourteen-year tenure at Purdue Pharma L.P., where she served as Vice President and Associate General Counsel. While at Purdue, Ms. Abrams was Purdue’s primary legal contact with government entities including the Department of Justice, Drug Enforcement Administration and other federal, state and local authorities. Ms. Abrams also served as Purdue’s liaison with congressional committees and caucuses that focused on issues related to Purdue’s products, such as abuse and diversion of opioid pharmaceutical products. Ms. Abrams also oversaw Purdue’s legal regulatory, employment, and government litigation groups. Prior to Purdue, Ms. Abrams served as an Assistant United States Attorney in the Southern District of New York and prior to that, Ms. Abrams clerked for then-Chief Judge Jack B. Weinstein, federal District Court, Eastern District of New York. Ms. Abrams earned her Juris Doctor degree from New York University School of Law, and her Bachelor of Arts degree from Cornell University. Ms. Abrams has extensive expertise in the pharmaceutical and biotechnology industries with nearly 20 years in senior legal roles.
- Richard S. Nelson
-
Richard S. Nelson，自2020年11月起担任董事。自2024年5月起，Nelson先生担任首席商务官，此前自2022年8月起担任企业发展执行副总裁。此前，纳尔逊先生在2022年3月至2022年8月期间担任临时首席执行官。Nelson先生还从2015年8月至今担任Vericast的企业发展执行副总裁。在加入Vericast之前，Nelson先生曾在多家上市公司和私营公司担任高级企业和业务发展职务，包括尼尔森公司、IAC/InterActive Corp.和Trendum。Nelson先生的职业生涯始于Skadden，Arps，Slate，Meagher & Flom，LLP的并购律师。Nelson先生在密歇根大学罗斯商学院获得了金融领域的工商管理学士学位，并在纽约大学法学院获得了法学博士学位。尼尔森先生是密歇根大学罗格尔癌症中心的国家顾问委员会成员，也是Think Pink Rocks乳腺癌慈善机构的董事会成员。
Richard S. Nelson,has served as a director on board since November 2020. Since May 2024, Mr. Nelson has served as chief business officer and previously served as executive vice president, corporate development since August 2022. Previously, Mr. Nelson served as interim chief executive officer from March 2022 until August 2022. Mr. Nelson also has served as executive vice president, corporate development for Vericast from August 2015 to the present. Prior to joining Vericast, Mr. Nelson held senior corporate and business development positions with multiple public and private companies, including The Nielsen Company, IAC/InterActive Corp. and Trendum. Mr. Nelson began his career as a mergers and acquisition attorney at Skadden, Arps, Slate, Meagher & Flom, LLP. Mr. Nelson earned his B.A. of business administration in finance from the Ross School of Business at the University of Michigan and a J.D. from New York University School of Law. Mr. Nelson is a member of the National Advisory Board for the University of Michigan Rogel Cancer Center and a member of the board of directors of Think Pink Rocks breast cancer charity. - Richard S. Nelson，自2020年11月起担任董事。自2024年5月起，Nelson先生担任首席商务官，此前自2022年8月起担任企业发展执行副总裁。此前，纳尔逊先生在2022年3月至2022年8月期间担任临时首席执行官。Nelson先生还从2015年8月至今担任Vericast的企业发展执行副总裁。在加入Vericast之前，Nelson先生曾在多家上市公司和私营公司担任高级企业和业务发展职务，包括尼尔森公司、IAC/InterActive Corp.和Trendum。Nelson先生的职业生涯始于Skadden，Arps，Slate，Meagher & Flom，LLP的并购律师。Nelson先生在密歇根大学罗斯商学院获得了金融领域的工商管理学士学位，并在纽约大学法学院获得了法学博士学位。尼尔森先生是密歇根大学罗格尔癌症中心的国家顾问委员会成员，也是Think Pink Rocks乳腺癌慈善机构的董事会成员。
- Richard S. Nelson,has served as a director on board since November 2020. Since May 2024, Mr. Nelson has served as chief business officer and previously served as executive vice president, corporate development since August 2022. Previously, Mr. Nelson served as interim chief executive officer from March 2022 until August 2022. Mr. Nelson also has served as executive vice president, corporate development for Vericast from August 2015 to the present. Prior to joining Vericast, Mr. Nelson held senior corporate and business development positions with multiple public and private companies, including The Nielsen Company, IAC/InterActive Corp. and Trendum. Mr. Nelson began his career as a mergers and acquisition attorney at Skadden, Arps, Slate, Meagher & Flom, LLP. Mr. Nelson earned his B.A. of business administration in finance from the Ross School of Business at the University of Michigan and a J.D. from New York University School of Law. Mr. Nelson is a member of the National Advisory Board for the University of Michigan Rogel Cancer Center and a member of the board of directors of Think Pink Rocks breast cancer charity.
- John A. Fry
-
John A. Fry，他于2016年3月被任命为董事会成员。Fry先生自2010年起担任Drexel大学的校长。从2002年到2010年，他担任Franklin & Marshall College的总裁；从1995年到2002年，他担任Pennsylvania大学的执行副总裁。在加入Pennsylvania大学之前，他是高等教育和非营利部门的管理顾问。他曾与一些全国一流的学院和大学密切合作，首先是与KPMG Peat Marwick合作，然后是与Coopers & Lybrand的全国高等教育咨询业务合作，在那里他被选为该公司的合伙人，并最终成为负责全国业务的合伙人。他是Community Health Systems（一般急症护理医院的领先运营商）、Macquarie Investment Management（前身为Delaware Investments，一家美国资产管理公司）和FS Investments（一家资产管理公司）的董事会成员。他持有Lafayette College的学士学位和New York大学Stern School of business的工商管理硕士学位。
John A. Fry was appointed to Board of Directors in March 2016. Mr. Fry has served as President of Drexel University since 2010. From 2002 to 2010 Mr. Fry served as the President of Franklin & Marshall College and from 1995 to 2002 he served as Executive Vice President of the University of Pennsylvania. Prior to joining the University of Pennsylvania, Mr. Fry was a management consultant for the higher education and nonprofit sectors. He worked closely with some of the nation's premier colleges and universities, first with KPMG Peat Marwick and then with Coopers & Lybrand's National Higher Education Consulting Practice where he was elected a partner in the firm and eventually became partner-in-charge of the national practice. Mr. Fry is a member of the Board of Directors of Community Health Systems, a leading operator of general acute care hospitals, Macquarie Investment Management formerly Delaware Investments, a U.S. based asset management firm, and FS Investments, an asset management firm. Mr. Fry holds a bachelor's degree from Lafayette College and a master's degree in business administration from the New York University Stern School of Business. - John A. Fry，他于2016年3月被任命为董事会成员。Fry先生自2010年起担任Drexel大学的校长。从2002年到2010年，他担任Franklin & Marshall College的总裁；从1995年到2002年，他担任Pennsylvania大学的执行副总裁。在加入Pennsylvania大学之前，他是高等教育和非营利部门的管理顾问。他曾与一些全国一流的学院和大学密切合作，首先是与KPMG Peat Marwick合作，然后是与Coopers & Lybrand的全国高等教育咨询业务合作，在那里他被选为该公司的合伙人，并最终成为负责全国业务的合伙人。他是Community Health Systems（一般急症护理医院的领先运营商）、Macquarie Investment Management（前身为Delaware Investments，一家美国资产管理公司）和FS Investments（一家资产管理公司）的董事会成员。他持有Lafayette College的学士学位和New York大学Stern School of business的工商管理硕士学位。
- John A. Fry was appointed to Board of Directors in March 2016. Mr. Fry has served as President of Drexel University since 2010. From 2002 to 2010 Mr. Fry served as the President of Franklin & Marshall College and from 1995 to 2002 he served as Executive Vice President of the University of Pennsylvania. Prior to joining the University of Pennsylvania, Mr. Fry was a management consultant for the higher education and nonprofit sectors. He worked closely with some of the nation's premier colleges and universities, first with KPMG Peat Marwick and then with Coopers & Lybrand's National Higher Education Consulting Practice where he was elected a partner in the firm and eventually became partner-in-charge of the national practice. Mr. Fry is a member of the Board of Directors of Community Health Systems, a leading operator of general acute care hospitals, Macquarie Investment Management formerly Delaware Investments, a U.S. based asset management firm, and FS Investments, an asset management firm. Mr. Fry holds a bachelor's degree from Lafayette College and a master's degree in business administration from the New York University Stern School of Business.
- Noel J. Spiegel
-
Noel J. Spiegel ，他一直担任我们的董事（2013年5月6日以来）。他目前担任American Eagle Outfitters公司的董事，在那里他担任审计委员会主席和薪酬委员会的成员。他目前也担任Radian Group公司的董事，在那里他担任审计委员会成员。他曾担任德勤会计师事务所（Deloitte & Touche）的合伙人（从1969年9月到2010年5月退休）。任职Deloitte公司超过四十年的职业生涯中，他曾担任多种管理职务，包括副执行合伙人、执行委员会成员、 Deloitte公司纽约办公室的负责审计业务的合伙人。他也曾担任Deloitte公司的管理合伙人，负责事务保证实践、全球发行和国际财务报告准则实践、实践，以及东北地区的科技、媒体和电信。他持有Long Island University的学士学位，也曾出席哈佛商学院（Harvard Business School）的进阶管理课程（Advanced Management Program）。
Noel J. Spiegel was a partner at Deloitte & Touche, LLP ("Deloitte"), where he practiced from September 1969 until his retirement in May 2010. In his over 40 year career at Deloitte, he served in numerous management positions, including as Deputy Managing Partner, member of the Executive Committee, Managing Partner of Deloitte's Transaction Assurance practice, Global Offerings and IFRS practice and Technology, Media and Telecommunications practice (Northeast Region), and as Partner in Charge of Audit Operations in Deloitte's New York office. Mr. Spiegel holds a B.S. from Long Island University and he attended the Advanced Management Program at Harvard Business School. - Noel J. Spiegel ，他一直担任我们的董事（2013年5月6日以来）。他目前担任American Eagle Outfitters公司的董事，在那里他担任审计委员会主席和薪酬委员会的成员。他目前也担任Radian Group公司的董事，在那里他担任审计委员会成员。他曾担任德勤会计师事务所（Deloitte & Touche）的合伙人（从1969年9月到2010年5月退休）。任职Deloitte公司超过四十年的职业生涯中，他曾担任多种管理职务，包括副执行合伙人、执行委员会成员、 Deloitte公司纽约办公室的负责审计业务的合伙人。他也曾担任Deloitte公司的管理合伙人，负责事务保证实践、全球发行和国际财务报告准则实践、实践，以及东北地区的科技、媒体和电信。他持有Long Island University的学士学位，也曾出席哈佛商学院（Harvard Business School）的进阶管理课程（Advanced Management Program）。
- Noel J. Spiegel was a partner at Deloitte & Touche, LLP ("Deloitte"), where he practiced from September 1969 until his retirement in May 2010. In his over 40 year career at Deloitte, he served in numerous management positions, including as Deputy Managing Partner, member of the Executive Committee, Managing Partner of Deloitte's Transaction Assurance practice, Global Offerings and IFRS practice and Technology, Media and Telecommunications practice (Northeast Region), and as Partner in Charge of Audit Operations in Deloitte's New York office. Mr. Spiegel holds a B.S. from Long Island University and he attended the Advanced Management Program at Harvard Business School.
- Hersh Kozlov
-
Hersh Kozlov，在诉讼、联邦和州监管事务、博彩法和复杂金融机构管理领域为客户提供咨询服务方面拥有超过三十年的法律经验。Kozlov先生自2009年以来一直是国际律师事务所Duane Morris LLP的合伙人，并担任该律师事务所的董事会成员。Previoly，2001年至2009年，他是Wolf，Block，Schorr and Solis 科恩 LLP律师事务所的合伙人。Kozlov先生目前在The Bancorp, Inc.（TBBK；纳斯达克）董事会任职。Kozlov Previoly先生于2019年9月至2023年2月期间担任生物制药公司vTv Therapeutics，Inc.（纳斯达克：VTVT）的董事会独立成员，还曾在Resce America，Inc.（REXI；NASDAQ）、JeffBanks，Inc.（JEFF；NASDAQ）、TRM Corporation（TRM；NASDAQ）、Hudson United Bank（HUB；NYSE）、美国医疗保健人寿保险公司和普林斯顿保险公司的董事会任职。此外，Kozlov先生被美国总统任命为贸易政策与谈判咨询委员会成员，在2002年至2004年担任该职务。Kozlov先生拥有Temple大学的学士学位和Case Stern Reserve大学法学院的法学博士学位。
Hersh Kozlov has served as a director of The Bancorp since 2014. He has been a partner at Duane Morris LLP ("Duane Morris"), an international law firm, since 2009 and serves on the governing board of the law firm. Mr. Kozlov also serves on the board of directors of BTC Development Corp. (NASDAQ: BDCIU). Previously, he was a partner at the law firm Wolf, Block, Schorr & Solis Cohen LLP from 2001 to 2009. Mr. Kozlov previously served as an independent member of the board of directors of vTv Therapeutics, Inc. (Nasdaq: VTVT), a biopharmaceutical company, from September 2019 through February 2024, and also has served on the board of directors of Resource America, Inc., JeffBanks, Inc., TRM Corporation, Hudson United Bank, U.S. Healthcare Life Insurance Company, and Princeton Insurance Company. In addition, Mr. Kozlov was appointed by the President of the United States to be a member of the Advisory Committee for Trade Policy & Negotiations, serving in that role from 2002 to 2004. - Hersh Kozlov，在诉讼、联邦和州监管事务、博彩法和复杂金融机构管理领域为客户提供咨询服务方面拥有超过三十年的法律经验。Kozlov先生自2009年以来一直是国际律师事务所Duane Morris LLP的合伙人，并担任该律师事务所的董事会成员。Previoly，2001年至2009年，他是Wolf，Block，Schorr and Solis 科恩 LLP律师事务所的合伙人。Kozlov先生目前在The Bancorp, Inc.（TBBK；纳斯达克）董事会任职。Kozlov Previoly先生于2019年9月至2023年2月期间担任生物制药公司vTv Therapeutics，Inc.（纳斯达克：VTVT）的董事会独立成员，还曾在Resce America，Inc.（REXI；NASDAQ）、JeffBanks，Inc.（JEFF；NASDAQ）、TRM Corporation（TRM；NASDAQ）、Hudson United Bank（HUB；NYSE）、美国医疗保健人寿保险公司和普林斯顿保险公司的董事会任职。此外，Kozlov先生被美国总统任命为贸易政策与谈判咨询委员会成员，在2002年至2004年担任该职务。Kozlov先生拥有Temple大学的学士学位和Case Stern Reserve大学法学院的法学博士学位。
- Hersh Kozlov has served as a director of The Bancorp since 2014. He has been a partner at Duane Morris LLP ("Duane Morris"), an international law firm, since 2009 and serves on the governing board of the law firm. Mr. Kozlov also serves on the board of directors of BTC Development Corp. (NASDAQ: BDCIU). Previously, he was a partner at the law firm Wolf, Block, Schorr & Solis Cohen LLP from 2001 to 2009. Mr. Kozlov previously served as an independent member of the board of directors of vTv Therapeutics, Inc. (Nasdaq: VTVT), a biopharmaceutical company, from September 2019 through February 2024, and also has served on the board of directors of Resource America, Inc., JeffBanks, Inc., TRM Corporation, Hudson United Bank, U.S. Healthcare Life Insurance Company, and Princeton Insurance Company. In addition, Mr. Kozlov was appointed by the President of the United States to be a member of the Advisory Committee for Trade Policy & Negotiations, serving in that role from 2002 to 2004.
高管简历
中英对照 | 中文 | 英文- Stephen L. Holcombe
Stephen L. Holcombe自2015年4月起担任公司的总裁和首席执行官。他自2014年起担任Predecessors的总裁，先前（2002年起）担任高级副总裁；他自2002年起担任Predecessors的财务总监。他拥有超过35年的财务和管理职位，专注于私人和公共融资、发展企业联盟战略、伙伴战略和管理和外部成分关系等方面的执行。在加入Predecessors之前他担任一下职位包括Vanguard Cellular Systems股份有限公司（Vanguard Cellular Systems, Inc，美国（United States）大型独立无线运营商之一）的执行副总裁和财务总监、BuildNet股份有限公司（BuildNet Inc，一家电子商务软件解决方案提供商）的执行副总裁和财务总监和KPMG Peat Marwick Mitchell不同职位。他拥有维克森林大学（Wake Forest University）会计学士学位。
Stephen L. Holcombe has served as our President and Chief Executive Officer since April 2015. Mr. Holcombe was the President and Chief Financial Officer of TransTech Pharma, LLC and High Point Pharmaceuticals, LLC, our predecessors, from 2014 to March 2015 where he previously served as Senior Vice President and Chief Financial Officer from 2002 to 2014. Mr. Holcombe has over 35 years of experience in financial and managerial roles focusing on the execution of private and public financings, developing corporate alliance and partnership strategies and managing relationships with external constituents. Positions that Mr. Holcombe held prior to joining our predecessors include Executive Vice President and Chief Financial Officer of Vanguard Cellular Systems, Inc., one of the largest independent wireless operators in the United States, Executive Vice President and Chief Financial Officer of BuildNet Inc., an e-commerce software solutions provider, and various positions with KPMG Peat Marwick Mitchell. He holds a bachelor’s degree in Accountancy from Wake Forest University.- Stephen L. Holcombe自2015年4月起担任公司的总裁和首席执行官。他自2014年起担任Predecessors的总裁，先前（2002年起）担任高级副总裁；他自2002年起担任Predecessors的财务总监。他拥有超过35年的财务和管理职位，专注于私人和公共融资、发展企业联盟战略、伙伴战略和管理和外部成分关系等方面的执行。在加入Predecessors之前他担任一下职位包括Vanguard Cellular Systems股份有限公司（Vanguard Cellular Systems, Inc，美国（United States）大型独立无线运营商之一）的执行副总裁和财务总监、BuildNet股份有限公司（BuildNet Inc，一家电子商务软件解决方案提供商）的执行副总裁和财务总监和KPMG Peat Marwick Mitchell不同职位。他拥有维克森林大学（Wake Forest University）会计学士学位。
- Stephen L. Holcombe has served as our President and Chief Executive Officer since April 2015. Mr. Holcombe was the President and Chief Financial Officer of TransTech Pharma, LLC and High Point Pharmaceuticals, LLC, our predecessors, from 2014 to March 2015 where he previously served as Senior Vice President and Chief Financial Officer from 2002 to 2014. Mr. Holcombe has over 35 years of experience in financial and managerial roles focusing on the execution of private and public financings, developing corporate alliance and partnership strategies and managing relationships with external constituents. Positions that Mr. Holcombe held prior to joining our predecessors include Executive Vice President and Chief Financial Officer of Vanguard Cellular Systems, Inc., one of the largest independent wireless operators in the United States, Executive Vice President and Chief Financial Officer of BuildNet Inc., an e-commerce software solutions provider, and various positions with KPMG Peat Marwick Mitchell. He holds a bachelor’s degree in Accountancy from Wake Forest University.
- Robin E. Abrams
Robin E.Abrams于2020年12月被任命为我们的董事会主席。在此之前，Abrams女士and General Counsel担任执行Vice President。Abrams女士目前还担任SIGA Technologies的总法律顾问兼首席行政官。在加入VTV之前，艾布拉姆斯女士在普渡制药公司（Purdue Pharma L.P.）任职14年，在那里她担任Vice President和副总法律顾问。在Purdue时，Abrams女士是Purdue与政府实体的主要法律联系，包括司法部，缉毒署和其他联邦，州和地方当局。Abrams女士还担任普渡公司与国会委员会和核心小组的联络人，这些委员会和核心小组专注于与普渡公司产品相关的问题，例如阿片类药物产品的滥用和转移。Abrams女士还监管Purdue&8217；的法律监管，就业和政府诉讼集团。在普渡之前，Abrams女士曾担任纽约南区美国助理检察官，在此之前，Abrams女士曾担任纽约东区联邦地区法院当时的首席法官Jack B.Weinstein的书记员。Abrams女士在纽约大学法学院（New York University School of Law）获得法学博士学位，在康奈尔大学（Cornell University）获得文学学士学位。Abrams女士在制药和生物技术行业拥有丰富的专业知识，担任了近20年的高级法律职务。
Robin E. Abrams was appointed Chairperson of our Board of Directors in December 2020. Prior to that, Ms. Abrams served as Executive Vice President and General Counsel. Ms. Abrams also currently serves as General Counsel and Chief Administrative Officer for SIGA Technologies. Prior to joining vTv, Ms. Abrams had a fourteen-year tenure at Purdue Pharma L.P., where she served as Vice President and Associate General Counsel. While at Purdue, Ms. Abrams was Purdue’s primary legal contact with government entities including the Department of Justice, Drug Enforcement Administration and other federal, state and local authorities. Ms. Abrams also served as Purdue’s liaison with congressional committees and caucuses that focused on issues related to Purdue’s products, such as abuse and diversion of opioid pharmaceutical products. Ms. Abrams also oversaw Purdue’s legal regulatory, employment, and government litigation groups. Prior to Purdue, Ms. Abrams served as an Assistant United States Attorney in the Southern District of New York and prior to that, Ms. Abrams clerked for then-Chief Judge Jack B. Weinstein, federal District Court, Eastern District of New York. Ms. Abrams earned her Juris Doctor degree from New York University School of Law, and her Bachelor of Arts degree from Cornell University. Ms. Abrams has extensive expertise in the pharmaceutical and biotechnology industries with nearly 20 years in senior legal roles.- Robin E.Abrams于2020年12月被任命为我们的董事会主席。在此之前，Abrams女士and General Counsel担任执行Vice President。Abrams女士目前还担任SIGA Technologies的总法律顾问兼首席行政官。在加入VTV之前，艾布拉姆斯女士在普渡制药公司（Purdue Pharma L.P.）任职14年，在那里她担任Vice President和副总法律顾问。在Purdue时，Abrams女士是Purdue与政府实体的主要法律联系，包括司法部，缉毒署和其他联邦，州和地方当局。Abrams女士还担任普渡公司与国会委员会和核心小组的联络人，这些委员会和核心小组专注于与普渡公司产品相关的问题，例如阿片类药物产品的滥用和转移。Abrams女士还监管Purdue&8217；的法律监管，就业和政府诉讼集团。在普渡之前，Abrams女士曾担任纽约南区美国助理检察官，在此之前，Abrams女士曾担任纽约东区联邦地区法院当时的首席法官Jack B.Weinstein的书记员。Abrams女士在纽约大学法学院（New York University School of Law）获得法学博士学位，在康奈尔大学（Cornell University）获得文学学士学位。Abrams女士在制药和生物技术行业拥有丰富的专业知识，担任了近20年的高级法律职务。
- Robin E. Abrams was appointed Chairperson of our Board of Directors in December 2020. Prior to that, Ms. Abrams served as Executive Vice President and General Counsel. Ms. Abrams also currently serves as General Counsel and Chief Administrative Officer for SIGA Technologies. Prior to joining vTv, Ms. Abrams had a fourteen-year tenure at Purdue Pharma L.P., where she served as Vice President and Associate General Counsel. While at Purdue, Ms. Abrams was Purdue’s primary legal contact with government entities including the Department of Justice, Drug Enforcement Administration and other federal, state and local authorities. Ms. Abrams also served as Purdue’s liaison with congressional committees and caucuses that focused on issues related to Purdue’s products, such as abuse and diversion of opioid pharmaceutical products. Ms. Abrams also oversaw Purdue’s legal regulatory, employment, and government litigation groups. Prior to Purdue, Ms. Abrams served as an Assistant United States Attorney in the Southern District of New York and prior to that, Ms. Abrams clerked for then-Chief Judge Jack B. Weinstein, federal District Court, Eastern District of New York. Ms. Abrams earned her Juris Doctor degree from New York University School of Law, and her Bachelor of Arts degree from Cornell University. Ms. Abrams has extensive expertise in the pharmaceutical and biotechnology industries with nearly 20 years in senior legal roles.
- Rudy C. Howard
Rudy C. Howard，自2022年6月3日起担任Aravive, Inc.首席财务官。2015年6月至2021年12月，霍华德先生担任vTv Therapeutics公司的首席财务官，该公司是一家临床阶段的制药公司，在纳斯达克资本市场上市（纳斯达克：VTVT）。在2010年1月至2015年5月加入vTv Therapeutics公司之前，Howard先生曾担任国际支出管理软件公司SciQuest，Inc.的首席财务官。从2008年11月到加入SciQuest，霍华德先生担任医药服务公司MDS Pharma Services的高级副总裁兼首席财务官。从2003年到加入MDS Pharma Services，霍华德先生在北卡罗来纳州威尔明顿经营自己的金融咨询公司Rudy C. Howard，CPA Consulting，他的服务包括为并购交易、股票和债券发行以及其他一般管理事务提供咨询。从2001年到2003年，霍华德先生担任国际人力资本管理软件公司Peopleclick公司的首席财务官。从2000年到加入Peopleclick，霍华德先生担任营销和互联网技术公司Marketing Services Group，Inc.的首席财务官。从1995年到2000年，霍华德先生担任临床研究机构PPD公司的首席财务官。在加入PPD之前，霍华德是普华永道的合伙人。霍华德先生拥有北卡罗来纳州立大学会计学学士学位，他是一名注册会计师。
Rudy C. Howard,has served as Aravive, Inc. Chief Financial Officer since June 3, 2022. From June 2015 through December 2021, Mr. Howard served as the Chief Financial Officer of vTv Therapeutics Inc., a clinical-stage pharmaceutical company listed on the Nasdaq Capital Market (Nasdaq: VTVT). Prior to joining vTv Therapeutics Inc., from January 2010 through May 2015, Mr. Howard served as the Chief Financial Officer of SciQuest, Inc., an international spend-management software company. From November 2008 until joining SciQuest, Mr. Howard served as Senior Vice President and Chief Financial Officer of MDS Pharma Services, a pharmaceutical services company. From 2003 until joining MDS Pharma Services, Mr. Howard operated his own financial consulting company, Rudy C. Howard, CPA Consulting, in Wilmington, North Carolina, where his services included advising on merger and acquisition transactions, equity and debt issuances and other general management matters. From 2001 through 2003, Mr. Howard served as Chief Financial Officer for Peopleclick, Inc., an international human capital management software company. From 2000 until joining Peopleclick, Mr. Howard served as Chief Financial Officer for Marketing Services Group, Inc., a marketing and internet technology company. From 1995 until 2000, Mr. Howard served as Chief Financial Officer for PPD, Inc., a clinical research organization. Prior to joining PPD, Mr. Howard was a partner with PricewaterhouseCoopers. Mr. Howard holds a B.A. in Accounting from North Carolina State University, and he is a Certified Public Accountant.- Rudy C. Howard，自2022年6月3日起担任Aravive, Inc.首席财务官。2015年6月至2021年12月，霍华德先生担任vTv Therapeutics公司的首席财务官，该公司是一家临床阶段的制药公司，在纳斯达克资本市场上市（纳斯达克：VTVT）。在2010年1月至2015年5月加入vTv Therapeutics公司之前，Howard先生曾担任国际支出管理软件公司SciQuest，Inc.的首席财务官。从2008年11月到加入SciQuest，霍华德先生担任医药服务公司MDS Pharma Services的高级副总裁兼首席财务官。从2003年到加入MDS Pharma Services，霍华德先生在北卡罗来纳州威尔明顿经营自己的金融咨询公司Rudy C. Howard，CPA Consulting，他的服务包括为并购交易、股票和债券发行以及其他一般管理事务提供咨询。从2001年到2003年，霍华德先生担任国际人力资本管理软件公司Peopleclick公司的首席财务官。从2000年到加入Peopleclick，霍华德先生担任营销和互联网技术公司Marketing Services Group，Inc.的首席财务官。从1995年到2000年，霍华德先生担任临床研究机构PPD公司的首席财务官。在加入PPD之前，霍华德是普华永道的合伙人。霍华德先生拥有北卡罗来纳州立大学会计学学士学位，他是一名注册会计师。
- Rudy C. Howard,has served as Aravive, Inc. Chief Financial Officer since June 3, 2022. From June 2015 through December 2021, Mr. Howard served as the Chief Financial Officer of vTv Therapeutics Inc., a clinical-stage pharmaceutical company listed on the Nasdaq Capital Market (Nasdaq: VTVT). Prior to joining vTv Therapeutics Inc., from January 2010 through May 2015, Mr. Howard served as the Chief Financial Officer of SciQuest, Inc., an international spend-management software company. From November 2008 until joining SciQuest, Mr. Howard served as Senior Vice President and Chief Financial Officer of MDS Pharma Services, a pharmaceutical services company. From 2003 until joining MDS Pharma Services, Mr. Howard operated his own financial consulting company, Rudy C. Howard, CPA Consulting, in Wilmington, North Carolina, where his services included advising on merger and acquisition transactions, equity and debt issuances and other general management matters. From 2001 through 2003, Mr. Howard served as Chief Financial Officer for Peopleclick, Inc., an international human capital management software company. From 2000 until joining Peopleclick, Mr. Howard served as Chief Financial Officer for Marketing Services Group, Inc., a marketing and internet technology company. From 1995 until 2000, Mr. Howard served as Chief Financial Officer for PPD, Inc., a clinical research organization. Prior to joining PPD, Mr. Howard was a partner with PricewaterhouseCoopers. Mr. Howard holds a B.A. in Accounting from North Carolina State University, and he is a Certified Public Accountant.
- Rudy C. Howard
Rudy C. Howard，2010年1月加入SciQuest，担任首席财务官。从2008年11月到加入SciQuest之间，他担任MDS医药服务公司的高级副总裁兼首席财务官，负责所有财务管理。从2003年到加入MDS期间，他运营位于北卡罗莱纳威尔明顿自己的金融咨询公司，他的专业咨询服务包括并购交易，股票和债券发行和其他综合管理问题。从2001年到2003年，他担任Peopleclick国际人力资源管理软件公司的首席财务官。从2000年到加入Peopleclick期间，他担任Marketing Services集团公司的首席财务官，该公司为营销和互联网技术公司。霍华德先生从1995年到2000年担任PPD公司的首席财务官，该公司为临床研究组织。加入PPD之前，他是PricewaterhouseCoopers的合伙人。他拥有北卡州立大学的会计学士学位。他是一个注册会计师。
Rudy C. Howard has served as our Chief Financial Officer since June 2015. Prior to joining vTv Therapeutics Inc., Mr. Howard served from January 2010 through May of 2015 as Chief Financial Officer of SciQuest, Inc., an international spend management software company. From November 2008 until joining SciQuest, Mr. Howard served as Senior Vice President and Chief Financial Officer of MDS Pharma Services, a pharmaceutical services company. From 2003 until joining MDS Pharma Services, Mr. Howard operated his own financial consulting company, Rudy C. Howard, CPA Consulting, in Wilmington, North Carolina, where his services included advising on merger and acquisition transactions, equity and debt issuances and other general management matters. From 2001 through 2003 Mr. Howard served as Chief Financial Officer for Peopleclick, Inc., an international human capital management software company. From 2000 until joining Peopleclick, Mr. Howard served as Chief Financial Officer for Marketing Services Group, Inc., a marketing and internet technology company. From 1995 until 2000 Mr. Howard served as Chief Financial Officer for PPD, Inc., a clinical research organization. Prior to joining PPD, Mr. Howard was a partner with PricewaterhouseCoopers. Mr. Howard holds a B.A. in Accounting from North Carolina State University, and he is a Certified Public Accountant.- Rudy C. Howard，2010年1月加入SciQuest，担任首席财务官。从2008年11月到加入SciQuest之间，他担任MDS医药服务公司的高级副总裁兼首席财务官，负责所有财务管理。从2003年到加入MDS期间，他运营位于北卡罗莱纳威尔明顿自己的金融咨询公司，他的专业咨询服务包括并购交易，股票和债券发行和其他综合管理问题。从2001年到2003年，他担任Peopleclick国际人力资源管理软件公司的首席财务官。从2000年到加入Peopleclick期间，他担任Marketing Services集团公司的首席财务官，该公司为营销和互联网技术公司。霍华德先生从1995年到2000年担任PPD公司的首席财务官，该公司为临床研究组织。加入PPD之前，他是PricewaterhouseCoopers的合伙人。他拥有北卡州立大学的会计学士学位。他是一个注册会计师。
- Rudy C. Howard has served as our Chief Financial Officer since June 2015. Prior to joining vTv Therapeutics Inc., Mr. Howard served from January 2010 through May of 2015 as Chief Financial Officer of SciQuest, Inc., an international spend management software company. From November 2008 until joining SciQuest, Mr. Howard served as Senior Vice President and Chief Financial Officer of MDS Pharma Services, a pharmaceutical services company. From 2003 until joining MDS Pharma Services, Mr. Howard operated his own financial consulting company, Rudy C. Howard, CPA Consulting, in Wilmington, North Carolina, where his services included advising on merger and acquisition transactions, equity and debt issuances and other general management matters. From 2001 through 2003 Mr. Howard served as Chief Financial Officer for Peopleclick, Inc., an international human capital management software company. From 2000 until joining Peopleclick, Mr. Howard served as Chief Financial Officer for Marketing Services Group, Inc., a marketing and internet technology company. From 1995 until 2000 Mr. Howard served as Chief Financial Officer for PPD, Inc., a clinical research organization. Prior to joining PPD, Mr. Howard was a partner with PricewaterhouseCoopers. Mr. Howard holds a B.A. in Accounting from North Carolina State University, and he is a Certified Public Accountant.